Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, prostate

1594 - In-depth assessment of metastatic prostate cancer with high tumour mutational burden


21 Oct 2018


Poster Discussion session - Genitourinary tumours, prostate


Tumour Site

Prostate Cancer


Niven Mehra


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


N. Mehra1, J. van Riet2, M. Smits1, H. Westdorp3, M. Gorris3, T. van Ee3, M. van der Doelen4, I. van Oort4, M. Sedelaar4, J. Textor3, E. Cuppen5, K. Grunberg6, M.J.L. Ligtenberg7, W. Zwart8, A. Bergman9, H.J.G. van de Werken2, J. Schalken10, I.J.M. de Vries3, M.P. Lolkema11, W.R. Gerritsen1

Author affiliations

  • 1 Medical Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 2 Department Of Cancer Computational Biology Center / Urology, Erasmus University Medical Center, 3015CN - Rotterdam/NL
  • 3 Department Of Tumour immunology, Radboud Institute for Molecular Life Sciences, 6525GA - Nijmegen/NL
  • 4 Urology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 5 Center For Molecular Medicine, University Medical Center Utrecht / Hartwig Medical Foundation / Center for Personalized Cancer Treatment, 3584CX - Utrecht/NL
  • 6 Department Of Pathology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 7 Department Of Pathology / Human Genetics, Radboud University Medical Center Nijmegen, 6500 HB - Nijmegen/NL
  • 8 Oncode Institute / Division Of Oncogenomics, Netherlands Cancer Institute (NKI-AVL), 1066CX - Amsterdam/NL
  • 9 Division Of Oncogenomics And Internal Medicine, Netherlands Cancer Institute (NKI-AVL), 1066CX - Amsterdam/NL
  • 10 Laboratory Of Experimental Urology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 11 Medical Oncology, Erasmus University Medical Center / Center for Personalized Cancer Therapy, 3075EA - Rotterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1594


A comprehensive assessment of biopsies from metastatic prostate cancer (mPCa) patients (pts) may identify a molecular subset of pts susceptible for immune checkpoint (IC) blockade (ICB).


148 biopsies and germline DNA from 145 mPCa pts were whole genome sequenced (WGS) at an average of 114x and 38x. Tumour mutational (mut) burden (TMB) was defined as number of somatic single nucleotide variants and InDels per Mb of the genome, known mut signatures (Alexandrov, Nature 2013) extracted by non-negative least squares regression as well as recurrent mutations reported in mismatch repair (MMR) pts (Kim, Cell 2013). Selected pts with high TMB were further evaluated for; (a) MMR protein expression; (b) multiplex intratumoural (IT) immune cell phenotyping (VECTRA); (c) multiplex IC expression (VECTRA); (d) 8-color flow cytometry blood immune cell phenotyping, with high TMB pts compared with low TMB pts. Pts receiving anti-PD-1 ICB had additional immune phenotyping at C2, C3, C4 and at progression; 3 pts had post-progression biopsies analyzed.


The median TMB was 2.9 (IQR 2.2 - 3.9); 12 pts (8.3%) had high TMB (>10 mut/Mb). In 11/12 pts with high TMB, corresponding MMR deficiency (MMRd) signatures (6, 15, 20 and 21) were identified. Recurrent mut in MMR genes were detected MSH2/MSH6, MSH3, MLH1; other recurrent mut were in POLE, and frameshift mut enriched (p < 0.001) in genes including TGFBR2, CLOCK, RPL22 and JAK1. Immunohistochemistry confirmed MMRd in 6/6 biopsies and in matched primary tissue in 5/5 evaluable pts. Five pts were referred for germline testing without MMR mut. A trend for increased IT CD3+ cells were seen in MMRd (p = 0.06); no relation was found between TMB and tumour PD-L1 expression. Pts were treated with anti-PD-1 ICB, with PSA>50% decline of 57% of hTMB pts (n = 7), and a significant decline in circulating T-cell populations during ICB, including CD4+PD-1 + (p = 0.02) and CD8+PD-1 + (p = 0.007). Response rate, duration of response, genomic and immune correlates will be presented for pts with low and high TMB.


8% of mPCa pts display a high TMB with recurrent somatic mut in MMR genes and POLE. MMRd appears early in PCa evolution. High TMB pts witness a high response rate to monotherapy anti-PD-1 ICB.

Clinical trial identification


Legal entity responsible for the study

Radboud University Medical Center.


This data and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) have made available to the study.

Editorial Acknowledgement


N. Mehra: Advisory board: Janssen; Honoraria: Bayer, Astellas, Janssen, MSD, BMS; Research funding: Astellas, Janssen. M. van der Doelen: Research grant: Bayer, the Netherlands. I. van Oort: Funding: Astellas, Janssen, Sanofi, Bayer. M.J.L. Ligtenberg: Research funds, Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.